NovoCure (NVCR) Stock Price, News & Analysis

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NVCR shares.
View NVCR analyst ratings or view top-rated stocks.

9 Wall Street analysts have issued 12 month price targets for NovoCure's stock. Their NVCR share price targets range from $15.00 to $51.00. On average, they predict the company's stock price to reach $30.88 in the next twelve months. This suggests a possible upside of 94.3% from the stock's current price.
View analysts price targets for NVCR or view top-rated stocks among Wall Street analysts.

NovoCure's stock was trading at $14.93 on January 1st, 2024. Since then, NVCR shares have increased by 6.4% and is now trading at $15.89.
View the best growth stocks for 2024 here.

NovoCure saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 6,040,000 shares, an increase of 20.6% from the March 31st total of 5,010,000 shares. Based on an average trading volume of 1,270,000 shares, the days-to-cover ratio is presently 4.8 days. Currently, 6.3% of the shares of the company are short sold.
View NovoCure's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 25th 2024.
View our NVCR earnings forecast.

NovoCure Limited (NASDAQ:NVCR) released its earnings results on Thursday, May, 2nd. The medical equipment provider reported ($0.36) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.43) by $0.07. The medical equipment provider earned $138.50 million during the quarter, compared to the consensus estimate of $131.44 million. NovoCure had a negative net margin of 36.67% and a negative trailing twelve-month return on equity of 50.35%. NovoCure's revenue for the quarter was up 13.3% on a year-over-year basis. During the same period in the prior year, the business earned ($0.50) EPS.

ETFs with the largest weight of NovoCure (NASDAQ:NVCR) stock in their portfolio include Counterpoint Quantitative Equity ETF (CPAI) and Amplify BlueStar Israel Technology ETF (ITEQ).iShares U.S. Medical Devices ETF (IHI).

17 employees have rated NovoCure Chief Executive Officer Asaf Danziger on Glassdoor.com. Asaf Danziger has an approval rating of 90% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other NovoCure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), NVIDIA (NVDA), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC), Viper Energy (VNOM), Roku (ROKU), Salesforce (CRM) and Block (SQ).

NovoCure's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (1.85%), SG Americas Securities LLC (0.33%), Russell Investments Group Ltd. (0.12%), Taylor Frigon Capital Management LLC (0.12%), SpiderRock Advisors LLC (0.08%) and Quantbot Technologies LP (0.06%). Insiders that own company stock include Asaf Danziger, Ashley Cordova, Ely Benaim, Frank X Leonard, Frank X Leonard, Gabriel Leung, Jeryl L Hilleman, Martin J Madden, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle.
View institutional ownership trends.

Shares of NVCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.